196 related articles for article (PubMed ID: 26254430)
1. Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer.
Qi L; Chen L; Li Y; Qin Y; Pan R; Zhao W; Gu Y; Wang H; Wang R; Chen X; Guo Z
Brief Bioinform; 2016 Mar; 17(2):233-42. PubMed ID: 26254430
[TBL] [Abstract][Full Text] [Related]
2. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
3. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.
Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH
Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826
[TBL] [Abstract][Full Text] [Related]
4. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
Wan YW; Beer DG; Guo NL
Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
[TBL] [Abstract][Full Text] [Related]
5. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.
Lu Y; Lemon W; Liu PY; Yi Y; Morrison C; Yang P; Sun Z; Szoke J; Gerald WL; Watson M; Govindan R; You M
PLoS Med; 2006 Dec; 3(12):e467. PubMed ID: 17194181
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Franzini A; Baty F; Macovei II; Dürr O; Droege C; Betticher D; Grigoriu BD; Klingbiel D; Zappa F; Brutsche MH
Clin Cancer Res; 2015 Dec; 21(23):5253-63. PubMed ID: 25922429
[TBL] [Abstract][Full Text] [Related]
7. Stable Gene Signature Selection for Prediction of Breast Cancer Recurrence Using Joint Mutual Information.
Sehhati M; Mehridehnavi A; Rabbani H; Pourhossein M
IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(6):1440-8. PubMed ID: 26671813
[TBL] [Abstract][Full Text] [Related]
8. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
Tang H; Wang S; Xiao G; Schiller J; Papadimitrakopoulou V; Minna J; Wistuba II; Xie Y
Ann Oncol; 2017 Apr; 28(4):733-740. PubMed ID: 28200038
[TBL] [Abstract][Full Text] [Related]
10. Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.
Sakashita H; Inoue H; Akamine S; Ishida T; Inase N; Shirao K; Mori M; Mimori K
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S590-8. PubMed ID: 23812770
[TBL] [Abstract][Full Text] [Related]
11. A 10-Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non-Small Cell Lung Cancer.
Xu W; Jia G; Davie JR; Murphy L; Kratzke R; Banerji S
J Thorac Oncol; 2016 Dec; 11(12):2150-2160. PubMed ID: 27498386
[TBL] [Abstract][Full Text] [Related]
12. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation.
Botling J; Edlund K; Lohr M; Hellwig B; Holmberg L; Lambe M; Berglund A; Ekman S; Bergqvist M; Pontén F; König A; Fernandes O; Karlsson M; Helenius G; Karlsson C; Rahnenführer J; Hengstler JG; Micke P
Clin Cancer Res; 2013 Jan; 19(1):194-204. PubMed ID: 23032747
[TBL] [Abstract][Full Text] [Related]
13. Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
Subramanian J; Simon R
J Natl Cancer Inst; 2010 Apr; 102(7):464-74. PubMed ID: 20233996
[TBL] [Abstract][Full Text] [Related]
14. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer.
Sanchez-Palencia A; Gomez-Morales M; Gomez-Capilla JA; Pedraza V; Boyero L; Rosell R; Fárez-Vidal ME
Int J Cancer; 2011 Jul; 129(2):355-64. PubMed ID: 20878980
[TBL] [Abstract][Full Text] [Related]
16. Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer.
Guan Q; Yan H; Chen Y; Zheng B; Cai H; He J; Song K; Guo Y; Ao L; Liu H; Zhao W; Wang X; Guo Z
BMC Genomics; 2018 Jan; 19(1):99. PubMed ID: 29378509
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
19. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
20. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
